ArriVent BioPharma, Inc. AVBP Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s change in accrued liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported change in accrued liabilities of -$3.83M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s change in accrued liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s change in accrued liabilities increased by 21.5% year-over-year, from -$4.88M to -$3.83M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s change in accrued liabilities?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s change in accrued liabilities has grown at a 107.0% compound annual growth rate (CAGR), from $1.56M to $6.67M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.